Álvaro H Borges1, Jacqueline Neuhaus2, Shweta Sharma2, James D Neaton2, Keith Henry3, Olga Anagnostou4, Teresa Staub5, Sean Emery6, Jens D Lundgren1. 1. Center of Excellence for Health, Infections and Immunity, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Denmark. 2. Division of Biostatistics, School of Public Health, University of Minnesota. 3. Hennepin County Medical Center, Minneapolis, Minnesota. 4. University of Athens, Greece. 5. Centre Hospitalier de Luxembourg, Service des Maladies Infectieuses, Luxembourg. 6. Faculty of Medicine, University of Queensland, Brisbane, Australia.
Abstract
Background: Pooled data from the SMART and START trials were used to compare deferred/intermittent versus immediate/continuous antiretroviral therapy (ART) on disease risk. Methods: Endpoints assessed were AIDS, serious non-AIDS (SNA), cardiovascular disease (CVD), cancer, and death. Pooled (stratified by study) hazard ratios (HRs) from Cox models were obtained for deferred/intermittent ART versus immediate/continuous ART; analyses were conducted to assess consistency of HRs across baseline-defined subgroups. Results: Among 10156 participants, there were 124 AIDS, 247 SNA, 117 cancers, 103 CVD, and 120 deaths. Interventions in each trial led to similar differences in CD4 count and viral suppression. Pooled HRs (95% confidence interval) of deferred/intermittent ART versus immediate/continuous ART were for AIDS 3.63 (2.37-5.56); SNA 1.62 (1.25-2.09); CVD 1.59 (1.07-2.37); cancer 1.93 (1.32-2.83); and death 1.80 (1.24-2.61). Underlying risk was greater in SMART than START. Given the similar HRs for each trial, absolute risk differences between treatment groups were greater in SMART than START. Pooled HRs were similar across subgroups. Conclusions: Treatment group differences in CD4 count and viral suppression were similar in SMART and START. Likely as a consequence, relative differences in risk of AIDS and SNA between immediate/continuous ART and deferred/intermittent ART were similar. Clinical Trials Registration: NCT00027352 and NCT00867048.
Background: Pooled data from the SMART and START trials were used to compare deferred/intermittent versus immediate/continuous antiretroviral therapy (ART) on disease risk. Methods: Endpoints assessed were AIDS, serious non-AIDS (SNA), cardiovascular disease (CVD), cancer, and death. Pooled (stratified by study) hazard ratios (HRs) from Cox models were obtained for deferred/intermittent ART versus immediate/continuous ART; analyses were conducted to assess consistency of HRs across baseline-defined subgroups. Results: Among 10156 participants, there were 124 AIDS, 247 SNA, 117 cancers, 103 CVD, and 120 deaths. Interventions in each trial led to similar differences in CD4 count and viral suppression. Pooled HRs (95% confidence interval) of deferred/intermittent ART versus immediate/continuous ART were for AIDS 3.63 (2.37-5.56); SNA 1.62 (1.25-2.09); CVD 1.59 (1.07-2.37); cancer 1.93 (1.32-2.83); and death 1.80 (1.24-2.61). Underlying risk was greater in SMART than START. Given the similar HRs for each trial, absolute risk differences between treatment groups were greater in SMART than START. Pooled HRs were similar across subgroups. Conclusions: Treatment group differences in CD4 count and viral suppression were similar in SMART and START. Likely as a consequence, relative differences in risk of AIDS and SNA between immediate/continuous ART and deferred/intermittent ART were similar. Clinical Trials Registration: NCT00027352 and NCT00867048.
Authors: Álvaro H Borges; Jacqueline Neuhaus; Abdel G Babiker; Keith Henry; Mamta K Jain; Adrian Palfreeman; Peter Mugyenyi; Pere Domingo; Christian Hoffmann; Tim R H Read; Sanjay Pujari; Michael Meulbroek; Margaret Johnson; Timothy Wilkin; Ronald Mitsuyasu Journal: Clin Infect Dis Date: 2016-09-08 Impact factor: 9.079
Authors: Abdel G Babiker; Sean Emery; Gerd Fätkenheuer; Fred M Gordin; Birgit Grund; Jens D Lundgren; James D Neaton; Sarah L Pett; Andrew Phillips; Giota Touloumi; Michael J Vjechaj Journal: Clin Trials Date: 2012-04-30 Impact factor: 2.486
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Justyna D Kowalska; Nina Friis-Møller; Ole Kirk; Wendy Bannister; Amanda Mocroft; Caroline Sabin; Peter Reiss; John Gill; Charlotte Lewden; Andrew Phillips; Antonella D'Arminio Monforte; Matthew Law; Jonathan Sterne; Stephane De Wit; Jens D Lundgren Journal: Epidemiology Date: 2011-07 Impact factor: 4.822
Authors: Alan R Lifson; Waldo H Belloso; Cate Carey; Richard T Davey; Daniel Duprez; Wafaa M El-Sadr; Jose M Gatell; Daniela C Gey; Jennifer F Hoy; Eric A Krum; Ray Nelson; Daniel E Nixon; Nick Paton; Court Pedersen; George Perez; Richard W Price; Ronald J Prineas; Frank S Rhame; James Sampson; John Worley Journal: HIV Clin Trials Date: 2008 May-Jun
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Leslie Cottle; Xinyi C Zhang; Joseph Makhema; Lisa A Mills; Ravindre Panchia; Sharlaa Faesen; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David D Celentano; Max Essex; Sarah E Hudelson; Andrew D Redd; Thomas R Fleming Journal: N Engl J Med Date: 2016-07-18 Impact factor: 91.245
Authors: Jason V Baker; Shweta Sharma; Birgit Grund; Adam Rupert; Julia A Metcalf; Mauro Schechter; Paula Munderi; Inka Aho; Sean Emery; Abdel Babiker; Andrew Phillips; Jens D Lundgren; James D Neaton; H Clifford Lane Journal: Open Forum Infect Dis Date: 2017-11-28 Impact factor: 3.835
Authors: Jason V Baker; Shweta Sharma; Amit C Achhra; Jose Ignacio Bernardino; Johannes R Bogner; Daniel Duprez; Sean Emery; Brian Gazzard; Jonathan Gordin; Greg Grandits; Andrew N Phillips; Siegfried Schwarze; Elsayed Z Soliman; Stephen A Spector; Giuseppe Tambussi; Jens Lundgren Journal: J Am Heart Assoc Date: 2017-05-22 Impact factor: 5.501
Authors: Jason V Baker; Katherine Huppler Hullsiek; Nicole Wyman Engen; Ray Nelson; Ploenchan Chetchotisakd; Jan Gerstoft; Heiko Jessen; Marcelo Losso; Norman Markowitz; Paula Munderi; Antonios Papadopoulos; Jonathan Shuter; Claire Rappoport; Mary T Pearson; Elizabeth Finley; Abdel Babiker; Sean Emery; Daniel Duprez Journal: Open Forum Infect Dis Date: 2016-10-08 Impact factor: 3.835
Authors: Wouter A van der Heijden; Rosanne C van Deuren; Lisa van de Wijer; Inge C L van den Munckhof; Marloes Steehouwer; Niels P Riksen; Mihai G Netea; Quirijn de Mast; Linos Vandekerckhove; Richarda M de Voer; Andre J van der Ven; Alexander Hoischen Journal: J Infect Dis Date: 2022-04-19 Impact factor: 7.759
Authors: Neval E Wareham; Qiuju Li; Henrik Sengeløv; Caspar Da Cunha-Bang; Finn Gustafsson; Carsten Heilmann; Michael Perch; Allan Rasmussen; Søren Schwartz Sørensen; Amanda Mocroft; Jens D Lundgren Journal: J Cancer Res Clin Oncol Date: 2019-11-05 Impact factor: 4.553
Authors: Christina Ekenberg; Joanne Reekie; Adrian G Zucco; Daniel D Murray; Shweta Sharma; Cameron R Macpherson; Abdel Babiker; Virginia Kan; H Clifford Lane; James D Neaton; Jens D Lundgren Journal: AIDS Date: 2021-04-01 Impact factor: 4.632
Authors: G V T Roozen; A G Vos; H A Tempelman; W D F Venter; D E Grobbee; K Scheuermaier; K Klipstein-Grobusch Journal: HIV Med Date: 2019-12-18 Impact factor: 3.180
Authors: Michael J Silverberg; Wendy Leyden; Raúl U Hernández-Ramírez; Li Qin; Haiqun Lin; Amy C Justice; Nancy A Hessol; Chad J Achenbach; Gypsyamber D'Souza; Eric A Engels; Keri N Althoff; Angel M Mayor; Timothy R Sterling; Mari M Kitahata; Ronald J Bosch; Michael S Saag; Charles S Rabkin; Michael A Horberg; M John Gill; Surbhi Grover; W Christopher Mathews; Jun Li; Heidi M Crane; Stephen J Gange; Bryan Lau; Richard D Moore; Robert Dubrow; Romain S Neugebauer Journal: Clin Infect Dis Date: 2021-06-01 Impact factor: 9.079